Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Organisation › Details

Nuevolution (Group)

Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into licensing agreements with Nuevolution. Nuevolution has entered a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $4 million budgeted project is supported by the Danish High Technology Fund. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution. Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolutions internal programs are focused on therapeutically important targets within inflammation and oncology. Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences. *

 

Period Start 2015-12-07 existent
Products Industry drug discovery services
  Industry 2 Chemetics® drug discovery technology
Persons Person Gouliaev, Alex Haahr (Nuevolution 201205 CEO + Co-founder before NeuroSearch)
  Person 2 Simonsen, Henrik (Nuevolution 201509– CFO before Director Life Science at Corporate Finance at SEB)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 8 Rønnegade
  City 2100 København
  Tel +45-70-200987
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2015-09-30)
     
    * Document for �About Section�: Nuevolution A/S. (1/10/14). "Press Release: Nuevolution Announces Technology Licensing Agreement". Copenhagen.
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Nuevolution (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top